U.S. Markets open in 12 mins.

Alexion Pharmaceuticals, Inc. (ALXN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
98.50-2.58 (-2.55%)
At close: 4:00PM EDT

99.35 0.85 (0.86%)
Pre-Market: 8:59AM EDT

People also watch
REGNBMRNVRTXBIIBCELG

Alexion Pharmaceuticals, Inc.

100 College Street
New Haven, CT 06510
United States
203-272-2596
http://www.alexion.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees3,121

Key Executives

NameTitlePayExercisedAge
Mr. David John Anderson MBAChief Financial Officer and Exec. VP177.5kN/A68
Ms. Julie O'Neill MBAExec. VP of Global Operations1.08MN/A61
Dr. Martin MacKay Ph.D.Head of R&D and Exec. VP1.15M2.88M60
Mr. Carsten Thiel Ph.D.Chief Commercial Officer and Exec. VPN/AN/A53
Dr. Ludwig N. Hantson Ph.D.Chief Exec. Officer and DirectorN/AN/A54
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Corporate Governance

Alexion Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 8. The pillar scores are Audit: 10; Board: 2; Shareholder Rights: 2; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.